Yu Tang1, Shanhong Tang2, Sanyuan Hu1. 1. Department of General Surgery, Qilu Hospital of Shandong University Jinan 250012, Shandong Province, China. 2. Department of Digestion, General Hospital of Chengdu Military Command Chengdu 610083, Sichuan Province, China.
Abstract
BACKGROUND: Spleen-preserving distal pancreatectomy can be performed with splenic vessel preservation (SPDP-SVP) or splenic vessel resection (SPDP-SVR). This meta-analysis aimed to evaluate the clinical outcomes of patients undergoing SPDP-SVP or SPDP-SVR. METHOD: A systematic literature search of PubMed, Embase, and the Cochrane Library was performed. The operative time, estimated blood loss, postoperative complications, pancreatic fistula (Grade B+C) rates, splenic infarction rates, gastric/perigastric varices rates and postoperative hospital stay were evaluated. RevMan 5.3 software was used to evaluate the differences between groups. RESULTS: Nine studies involving 639 patients were included in this meta-analysis, of whom 402 underwent SPDP-SVP and 237 underwent SPDP-SVR. Patients who underwent SPDP-SVP had lower splenic infarction and gastric/perigastric varices rates. The operative time, estimated blood loss, postoperative complications, pancreatic fistula (Grade B+C) rates and postoperative hospital stays were comparable between these two groups. CONCLUSIONS: SPDP-SVP and SPDP-SVR are both safe, feasible procedures for the management of benign or low-grade malignant pancreatic body or tail tumors. However, SPDP-SVR is related to higher incidence rates of early splenic ischemia and gastric/perigastric varices.
BACKGROUND: Spleen-preserving distal pancreatectomy can be performed with splenic vessel preservation (SPDP-SVP) or splenic vessel resection (SPDP-SVR). This meta-analysis aimed to evaluate the clinical outcomes of patients undergoing SPDP-SVP or SPDP-SVR. METHOD: A systematic literature search of PubMed, Embase, and the Cochrane Library was performed. The operative time, estimated blood loss, postoperative complications, pancreatic fistula (Grade B+C) rates, splenic infarction rates, gastric/perigastric varices rates and postoperative hospital stay were evaluated. RevMan 5.3 software was used to evaluate the differences between groups. RESULTS: Nine studies involving 639 patients were included in this meta-analysis, of whom 402 underwent SPDP-SVP and 237 underwent SPDP-SVR. Patients who underwent SPDP-SVP had lower splenic infarction and gastric/perigastric varices rates. The operative time, estimated blood loss, postoperative complications, pancreatic fistula (Grade B+C) rates and postoperative hospital stays were comparable between these two groups. CONCLUSIONS:SPDP-SVP and SPDP-SVR are both safe, feasible procedures for the management of benign or low-grade malignant pancreatic body or tail tumors. However, SPDP-SVR is related to higher incidence rates of early splenic ischemia and gastric/perigastric varices.
Authors: Muhammad Umair Bashir; Apostolos Kandilis; Nancy M Jackson; Janak A Parikh; Michael J Jacobs Journal: Ann Hepatobiliary Pancreat Surg Date: 2020-05-31
Authors: Dae Joon Park; In Woong Han; Sang Hyup Han; Sun Jong Han; Young Hun You; Young Ju Rhu; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi Journal: Ann Surg Treat Res Date: 2018-02-26 Impact factor: 1.859